
Brixadi
Buprenorphine
- SKU
- 58284-208
- Mfr
- Braeburn Inc.
.16 ml in 1 syringe, glass, 1 syringe, glass in 1 carton
$441.60
Price for one pack
Controlled medicine — prescription required. Upload your prescription at checkout or email it to us after ordering. We ship once a pharmacist has checked it and confirmed it with your prescriber. How it works
BRIXADI is indicated for the treatment of moderate to severe opioid use disorder in patients who have initiated treatment with a single dose of a transmucosal buprenorphine product or who are already being treated with buprenorphine.
- Strength
- Buprenorphine 8 mg/.16mL
- Unit of measure
- Per .16mL
- Dosage form
- Injection
- Route
- Subcutaneous
Pharmacologic class
- Partial Opioid AgonistEstablished class
- Partial Opioid AgonistsMechanism
- Brand name
- Brixadi
- Generic name
- Buprenorphine
- Manufacturer
- Braeburn Inc.
- Product NDC (SKU)
- 58284-208
- Active ingredients
- Buprenorphine 8 mg/.16mL
- Unit of measure
- Per .16mL
- Dosage form
- Injection
- Route
- Subcutaneous
- DEA schedule
- CIII
- Product type
- HUMAN PRESCRIPTION DRUG
- Marketing category
- NDA
- Application number
- NDA210136
- Marketed since
- June 6, 2023
- Label revised
- December 31, 2025
| Package NDC | Description |
|---|---|
| 58284-208-01 | 1 SYRINGE, GLASS in 1 CARTON (58284-208-01) / .16 mL in 1 SYRINGE, GLASS |
Reading this NDC
58284-208-01
- 01Labeler code
- Braeburn Inc.
- 02Product code
- Brixadi, injection
- 03Package code
- 1 syringe, glass in 1 carton (58284-208-01) / .16 ml in 1 syringe, glass
BRIXADI contains buprenorphine, a partial agonist at the mu-opioid receptor and an antagonist at the kappa-opioid receptor.
Warning: Risk of serious harm or death with intravenous administration;
BRIXADI RISK EVALUATION AND MITIGATION STRATEGY Serious harm or death could result if administered intravenously. BRIXADI forms a liquid crystalline gel upon contact with body fluids and may cause occlusion, local tissue damage, and thrombo‐embolic events, including life-threatening pulmonary emboli, if administered intravenously.
Because of the risk of serious harm or death that could result from intravenous self‐administration, BRIXADI is only available through a restricted program called the BRIXADI REMS. Healthcare settings and pharmacies that order and dispense BRIXADI must be certified in this program and comply with the REMS requirements.
WARNING. RISK OF SERIOUS HARM OR DEATH WITH INTRAVENOUS ADMINISTRATION; BRIXADI RISK EVALUATION AND MITIGATION STRATEGY See full prescribing information for complete boxed warning. Serious harm or death could result if administered intravenously.
BRIXADI is only available through a restricted program called the BRIXADI REMS. Healthcare settings and pharmacies that order and dispense BRIXADI must be certified in this program and comply with the REMS requirements.
BRIXADI is indicated for the treatment of moderate to severe opioid use disorder in patients who have initiated treatment with a single dose of a transmucosal buprenorphine product or who are already being treated with buprenorphine. BRIXADI should be used as part of a complete treatment plan that includes counseling and psychosocial support. BRIXADI contains buprenorphine, a partial opioid agonist.
BRIXADI is indicated for the treatment of moderate to severe opioid use disorder in patients who have initiated treatment with a single dose of a transmucosal buprenorphine product or who are already being treated with buprenorphine.
BRIXADI should be used as part of a complete treatment plan that includes counseling and psychosocial support.
Read before you order

Opioid use disorder · 2 min read
How buprenorphine treatment for opioid use disorder works
Buprenorphine and buprenorphine-naloxone explained: how they reduce cravings and withdrawal, how treatment starts and why it is safer than full opioids.

Opioid use disorder · 2 min read
Naloxone: how to recognise and reverse an opioid overdose
How naloxone nasal spray works, the signs of an opioid overdose and step-by-step what to do while you wait for emergency help.

Opioid use disorder · 2 min read
Naltrexone and lofexidine: other medicines for opioid recovery
How naltrexone blocks opioids to prevent relapse, how lofexidine eases withdrawal symptoms, and who each is for.
More in Opioid Use Disorder
View all
Generic · Film
Buprenorphine And Naloxone
Buprenorphine Hydrochloride 8 mg/1, Naloxone Hydrochloride Dihydrate 2 mg/1
- SKU
- 0378-8767
- Mfr
- Mylan Pharmaceuticals Inc.
From $78.99Min. 4 packsPrescription required

Generic · Tablet
Buprenorphine Hydrochloride And Naloxone Hydrochloride Dihydrate
Buprenorphine Hydrochloride 8 mg/1, Naloxone Hydrochloride Dihydrate 2 mg/1
- SKU
- 0406-8020
- Mfr
- SpecGx LLC
From $29.99Min. 11 packsPrescription required

Generic · Tablet
Buprenorphine Hydrochloride And Naloxone Hydrochloride Dihydrate
Buprenorphine Hydrochloride 2 mg/1, Naloxone Hydrochloride Dihydrate .5 mg/1
- SKU
- 51407-948
- Mfr
- Golden State Medical Supply, Inc.
From $21.99Min. 14 packsPrescription required

Generic · Tablet
Buprenorphine
Buprenorphine Hydrochloride 2 mg/1
- SKU
- 63629-9475
- Mfr
- Bryant Ranch Prepack
From $11.99Min. 26 packsPrescription required